遗传变异与肝硬化关联:多性状全基因组关联及基因-环境交互研究
该多性状全基因组关联研究整合肝硬化和丙氨酸氨基转移酶水平,在5个发现研究(含4829例肝硬化和72705例对照)中识别出12个与肝硬化相关的独立遗传变异,其中7个为新发现,并在3个复制研究中验证。这些变异构建的多基因评分可识别肝硬化高风险人群,且过量饮酒或肥胖会显著放大极端多基因风险的肝硬化概率。
要点
- 12个独立遗传变异与肝硬化相关,其中7个为新发现。
- 多基因评分最高五分位者肝硬化风险显著增加(OR 2.26)。
- 极端多基因风险(前1%)者风险更高(OR 3.16)。
核心结论
- 12个独立遗传变异(7个为新发现) confer 肝硬化风险,聚合为多基因评分可识别高风险人群。
- 极端多基因风险个体对过量饮酒或肥胖的肝毒性效应更易感。
研究设计与样本
- 多性状全基因组关联研究,在5个发现研究中联合分析肝硬化与丙氨酸氨基转移酶水平,包括4829例肝硬化和72705例对照,以及362539例ALT水平个体。
- 在3个复制研究(Partners HealthCare Biobank、FinnGen、Biobank Japan,含3554例肝硬化和343826例对照)中验证。
- 多基因评分在Partners HealthCare Biobank中测试。
主要发现
- 5个既往报道和7个新识别的遗传变异在发现研究(P < 5 × 10-8)和复制研究(P < .05)中均与肝硬化相关,包括APOE基因错义变异和EFN1A附近非编码变异。
- Partners HealthCare Biobank中,多基因评分最高五分位者肝硬化风险显著增加(OR 2.26;P < .001)。
- 极端多基因风险(前1%)者肝硬化风险更高(OR 3.16;P < .001)。
- 极端多基因风险者75岁前肝硬化概率随饮酒量增加分别为13.7%、20.1%、48.2%(Pinteraction < .001)。
- 极端多基因风险者75岁前肝硬化概率随体重状态分别为正常体重6.5%、超重10.3%、肥胖19.5%(Pinteraction < .001)。
关键数值与推荐
- 多基因评分最高五分位与最低五分位相比,肝硬化OR 2.26(P < .001)。
- 多基因评分前1%与最低五分位相比,肝硬化OR 3.16(P < .001)。
- 极端多基因风险者75岁前肝硬化概率:无/少量饮酒13.7%,中度饮酒20.1%,增加饮酒48.2%(Pinteraction < .001)。
- 极端多基因风险者75岁前肝硬化概率:正常体重6.5%,超重10.3%,肥胖19.5%(Pinteraction < .001)。
临床怎么用
- 多基因评分可用于肝硬化遗传风险分层,识别高风险个体。
- 对极端多基因风险个体,应重点干预过量饮酒和肥胖以降低肝硬化风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: In contrast to most other common diseases, few genetic variants have been identified that impact risk of cirrhosis. We aimed to identify new genetic variants that predispose to cirrhosis, to test whether such variants, aggregated into a polygenic score, enable genomic risk stratification, and to test whether alcohol intake or body mass index interacts with polygenic predisposition. METHODS: We conducted a multi-trait genome-wide association study combining cirrhosis and alanine aminotransferase levels performed in 5 discovery studies (UK Biobank, Vanderbilt BioVU, Atherosclerosis Risk in Communities study, and 2 case-control studies including 4829 individuals with cirrhosis and 72,705 controls and 362,539 individuals with alanine aminotransferase levels). Identified variants were replicated in 3 studies (Partners HealthCare Biobank, FinnGen, and Biobank Japan including 3554 individuals with cirrhosis and 343,826 controls). A polygenic score was tested in Partners HealthCare Biobank. RESULTS: Five previously reported and 7 newly identified genetic variants were associated with cirrhosis in both the discovery studies multi-trait genome-wide association study (P < 5 × 10-8) and the replication studies (P < .05), including a missense variant in the APOE gene and a noncoding variant near EFN1A. These 12 variants were used to generate a polygenic score. Among Partners HealthCare Biobank individuals, high polygenic score-defined as the top quintile of the distribution-was associated with significantly increased risk of cirrhosis (odds ratio, 2.26; P < .001) and related comorbidities compared with the lowest quintile. Risk was even more pronounced among those with extreme polygenic risk (top 1% of the distribution, odds ratio, 3.16; P < .001). The impact of extreme polygenic risk was substantially more pronounced in those with elevated alcohol consumption or body mass index. Modeled as risk by age 75 years, probability of cirrhosis with extreme polygenic risk was 13.7%, 20.1%, and 48.2% among individuals with no or modest, moderate, and increased alcohol consumption, respectively (Pinteraction < .001). Similarly, probability among those with extreme polygenic risk was 6.5%, 10.3%, and 19.5% among individuals with normal weight, overweight, and obesity, respectively (Pinteraction < .001). CONCLUSIONS: Twelve independent genetic variants, 7 of which are newly identified in this study, conferred risk for cirrhosis. Aggregated into a polygenic score, these variants identified a subset of the population at substantially increased risk who are most susceptible to the hepatotoxic effects of excess alcohol consumption or obesity.
引用
- Emdin CA, Haas M, Ajmera V, et al. Association of Genetic Variation With Cirrhosis: A Multi-Trait Genome-Wide Association and Gene-Environment Interaction Study. Gastroenterology. 2020. PMID: 33310085. doi:10.1053/j.gastro.2020.12.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。